<DOC>
	<DOCNO>NCT00212862</DOCNO>
	<brief_summary>The purpose study describe patient characteristic , treatment pattern , clinical outcome adult patient cancer receive erythropoiesis-stimulating therapy ( EST ) .</brief_summary>
	<brief_title>Dosing Outcomes Study Erythropoietic Stimulating Therapies Patients With Chemotherapy Induced Anemia</brief_title>
	<detailed_description>The Dosing Outcomes Study Erythropoietic Stimulating Therapies ( DOSE ) prospective , observational multicenter registry approximately 1200 adult cancer patient receive treatment EST ; eg , epoetin alfa darbepoetin alfa . The planned duration DOSE Registry three year . Based initial result , registry sponsor may elect extend duration registry.This study specify treatment protocol , require particular assignment patient treatment protocol , way require participate physician alter practice pattern . Participating physician instruct continue treat patient accord best clinical judgment , submit information baseline patient characteristic , treatment pattern , clinical outcome . Baseline determination include patient demographic , tumor treatment type , hematologic parameter , patient report outcome . Data collect 16-week study period regard EST treatment , hematologic outcome patient report outcome .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<criteria>Patients cancer treat erythropoiesisstimulating therapy ( EST ) anemia cancer cancerrelated treatment Must EST `` naive '' globally must treatment EST least 90 day Must speak read english able answer type simple question present patient questionnaire If patient identify study inpatient , must able follow 16 week The patient must give consent participate registry signing informed consent form Patients currently participate clinical study EST ( however , patient may undergo treatment investigational cancer treatment protocol ) Have dialysis end stage renal disease past Has myelodysplasia myelodysplastic syndrome Patients know need stem cell transplant Patient selfadminister epoetin alfa darbepoetin alfa</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Cancer</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>Darbepoetin alfa</keyword>
	<keyword>Registry</keyword>
</DOC>